We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
(-13%)
Cap. Flow
-$196M
Cap. Flow
% of AUM
-6.55%
Top 10 Holdings %
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15
Avg Time Held Equity + Options
8.8
quarters
Top 10 Avg Time Held Equity + Options
5.7
quarters
Top 20 Avg Time Held Equity + Options
5.8
quarters
Avg Time Held Equity only
9.8
quarters
Top 10 Avg Time Held Equity only
5.7
quarters
Top 20 Avg Time Held Equity only
5.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$40.3M |
| 2 |
argenx
ARGX
|
+$39.9M |
| 3 |
Revolution Medicines
RVMD
|
+$39.2M |
| 4 |
Immunovant
IMVT
|
+$29.2M |
| 5 |
RayzeBio, Inc. Common Stock
RYZB
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$68.3M |
| 2 |
Vir Biotechnology
VIR
|
+$48M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$46.2M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$35.7M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$33.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.21% |
| 2 | Miscellaneous | 0.79% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SLGC
76
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $3.58M | 0.12% |
1,500,000
| – | – |
2021 Q3
8 quarters
|
|
77
Travere Therapeutics
TVTX
$4.88B
| $3.58M | 0.12% |
400,000
+309,252
| +341% | +$4.36M |
2014 Q1
38 quarters
|
|
78
CALL
Sarepta Therapeutics
SRPT
$1.74B
| $3.13M | 0.1% |
+100,000
| New | +$11.3M |
2023 Q3
0 quarters
|
|
|
PNT
79
PUT
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $2.63M | 0.09% |
800,000
+300,000
| +60% | +$2.49M |
2023 Q2
1 quarter
|
|
80
PUT
Arcutis Biotherapeutics
ARQT
$3.28B
| $2.62M | 0.09% |
300,000
| – | – |
2023 Q2
1 quarter
|
|
81
PUT
EyePoint Inc
EYPT
$265M
| $2.51M | 0.08% |
+750,000
| New | +$8.22M |
2023 Q3
0 quarters
|
|
82
DELISTED
Kronos Bio
KRON
| $2.28M | 0.08% |
1,752,745
| – | – |
2020 Q4
11 quarters
|
|
83
DELISTED
Forte Biosciences
FBRX
| $2.16M | 0.07% |
+130,614
| New | +$2.9M |
2023 Q3
0 quarters
|
|
84
DELISTED
ACELYRIN
SLRN
| $2.03M | 0.07% |
200,000
| – | – |
2023 Q2
1 quarter
|
|
85
CALL
DELISTED
89bio
ETNB
| $1.62M | 0.05% |
+400,000
| New | +$6.71M |
2023 Q3
0 quarters
|
|
86
PUT
Aclaris Therapeutics
ACRS
$511M
| $1.45M | 0.05% |
+500,000
| New | +$4.27M |
2023 Q3
0 quarters
|
|
87
Spyre Therapeutics
SYRE
$7.52B
| $994K | 0.03% |
+81,116
| New | +$1.07M |
2023 Q3
0 quarters
|
|
88
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $926K | 0.03% |
1,381,355
| – | – |
2015 Q1
34 quarters
|
|
89
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $900K | 0.03% |
78,774
| – | – |
2021 Q2
9 quarters
|
|
90
Veru
VERU
$37.3M
| $784K | 0.03% |
108,988
+100,000
| +1,113% | +$1.09M |
2018 Q3
20 quarters
|
|
91
CALL
Viking Therapeutics
VKTX
$3.39B
| $240K | 0.01% |
+300,000
| New | +$4.29M |
2023 Q3
0 quarters
|
|
|
92
PUT
DELISTED
Apellis Pharmaceuticals
APLS
| $72.5K | ﹤0.01% |
+100,000
| New | +$4.39M |
2023 Q3
0 quarters
|
|
93
Cypherpunk Technologies Inc
CYPH
$306M
| $62.1K | ﹤0.01% |
44,971
-541,762
| -92% | -$1.26M |
2020 Q1
14 quarters
|
|
|
MOTS
94
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
| $40.5K | ﹤0.01% |
6,002
| – | – |
2018 Q1
22 quarters
|
|
95
DELISTED
CareMax, Inc. Warrant
CMAXW
| $11.3K | ﹤0.01% |
60,000
| – | – |
2021 Q2
9 quarters
|
|
|
EQRXW
96
DELISTED
EQRx, Inc. Warrant
EQRXW
| $10K | ﹤0.01% |
250,000
| – | – |
2021 Q4
7 quarters
|
|
97
DELISTED
Surrozen Inc Warrant
SRZNW
| $6.67K | ﹤0.01% |
166,666
| – | – |
2021 Q3
8 quarters
|
|
|
98
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-812,037
| Closed | -$35.7M | – |
|
99
BioMarin Pharmaceuticals
BMRN
$10.5B
| – | – |
-263,207
| Closed | -$22.8M | – |
|
100
CALL
DELISTED
BioXcel Therapeutics
BTAI
| – | – |
-27,469
| Closed | -$11K | – |
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $196M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.
- Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
- Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
- Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
- Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
- Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
- Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.
Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.